Outcomes after cavotricuspid isthmus ablation: predictors of new-onset atrial fibrillation and stroke according to anticoagulation strategy

13 April 2026 (10:30 - 11:15)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Jose Carlos Villoria Martin

Juan Ramon Jimenez University Hospital, Huelva (Spain)

4 More presentations in this session

Presentation thumbnail

Impact of kidney function on cardiovascular outcome in patients with device-detected atrial fibrillation in NOAH-AFNET 6

Professor A. Goette (Paderborn, DE)

Abstract Slides Video

Presentation thumbnail

Ablation outcome and post-interventional management of anticoagulation in patients with obesity or severe obesity and atrial fibrillation

Ms R. Bares (Munich, DE)

Abstract Slides Video

Presentation thumbnail

Distribution of apixaban plasma concentrations across prescribed dose groups for ischemic stroke prevention in atrial fibrillation

Associate Professor K. Lim (Busan, KR)

Abstract Slides Video

Presentation thumbnail

CHA2DS2-VASc score-based anticoagulation management after catheter ablation for atrial fibrillation: a post-hoc analysis of the ALONE-AF trial

Doctor Y. Lee (Seoul, KR)

Abstract Slides Video

Access the full session

Session thumbnail

Oral anticoagulation in atrial fibrillation

The Event

Event poster

EHRA 2026

13 April 2026 10:30 CET

You may be interested in

Congress Presentation

Anticoagulation after cavotricuspid isthmus-dependent atrial flutter ablation: essential or overused?

Congress Presentation

Efficacy, safety and very long term recurrences of cavo-tricuspid isthmus-dependent atrial flutter ablation: a large multicenter observational study.

Congress Presentation

Cavotricuspid isthmus ablation using a pentaspline pulsed field ablation catheter: one-year outcomes.

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources